Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Beta Interferon on the Expression of Mir-145 in Patients With Multiple Sclerosis



Ehtesham N1 ; Sharifi M3 ; Khorvash F2 ; Kheirollahi M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease and Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2016

Abstract

Background: microRNAs are non-coding RNAs that modulate different types of cellular processes like differentiation and cell death. Hitherto several studies have been done to determine the expression profile of microRNAs in patients with multiple sclerosis (MS) to obtain appropriate biomarkers. In previous studies,it was found that miR-145 was over-expressed. This up-regulation was in patients who did not start taking medicine. Therefore,in this study we assessed the effect of beta interferon on the expression of this microRNA in patients with multiple sclerosis. Methods: We evaluated the expression pattern of miR-145 in 15 patients who did not start taking medicine and called treatment naive,in 15 patients who were under treatment and also 15 healthy people using real-time polymerase chain reaction method. Findings: The expression level of miR-145 in treatment naive patients was 3.9 fold of healthy people (P = 0.005),whereas expression level of this microRNA between healthy people and under treatment patients was not significantly different. Conclusion: Down-regulation of miR-145 in under-treatment patients to the extent of healthy people suggests that probably,this microRNA could be used as predictive biomarker. © 2016,Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
2. Micrornas: Key Modulators of Disease-Modifying Therapies in Multiple Sclerosis : Pancreatic Cancer Is One of the Lethal Malignant Tumours in the World.In This Study, We Investigated the Car T-Cell Therapy of Pancreatic Cancer, International Reviews of Immunology (2020)
3. The Role of Micrornas Involved in the Disorder of Blood–Brain Barrier in the Pathogenesis of Multiple Sclerosis, Frontiers in Immunology (2023)
4. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
5. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
6. Microrna-29B Variants and Mxa Expression Change During Interferon Beta Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2019)
7. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
8. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (29)
Vahid Shaygannejad (28)
Other Related Docs
9. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
10. Mir-326 and Mir-26A, Two Potential Markers for Diagnosis of Relapse and Remission Phases in Patient With Relapsing-Remitting Multiple Sclerosis, Gene (2014)
11. Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients, Cell Journal (2016)
12. Mir-504 Expression Level Is Increased in Multiple Sclerosis Patients Responder to Interferon-Beta, Journal of Neuroimmunology (2020)
13. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
14. Lncrnas Associated With Multiple Sclerosis Expressed in the Th1 Cell Lineage, Journal of Cellular Physiology (2019)
15. Analysis of the Expression of Mir-34A, Mir-199A, Mir-30C and Mir-19A in Peripheral Blood Cd4+T Lymphocytes of Relapsing-Remitting Multiple Sclerosis Patients, Gene (2018)
16. Potential Biomarker and Therapeutic Lncrnas in Multiple Sclerosis Through Targeting Memory B Cells, NeuroMolecular Medicine (2020)
17. Genetic Variation in Intergenic and Exonic Mirna Sequence and Risk of Multiple Sclerosis in the Isfahan Patients, Iranian Journal of Allergy, Asthma and Immunology (2018)
18. Study of the Correlation Between Mir-106A, Mir-125B, and Mir-330 on Multiple Sclerosis Patients by Targeting Tnfsf4 and Sp1 in Nf-Κb/Tnf-Α Pathway: A Case-Control Study, Cell Journal (2022)
19. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)
20. An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of Mir-21 on T-Cell Related Target Genes in Multiple Sclerosis, Avicenna Journal of Medical Biotechnology (2021)
21. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
22. Oleuropein As an Effective Suppressor of Inflammation and Microrna-146A Expression in Patients With Rheumatoid Arthritis, Cell Journal (2023)
23. Integrative Analysis of Lncrnas in Th17 Cell Lineage to Discover New Potential Biomarkers and Therapeutic Targets in Autoimmune Diseases, Molecular Therapy Nucleic Acids (2018)
24. The Comparative Analysis of Serum Levels of Midkine in Patients With Multiple Sclerosis and Control Group, Journal of Isfahan Medical School (2013)
25. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
26. Joint Application of Magnetic Resonance Imaging and Biochemical Biomarkers in Diagnosis of Multiple Sclerosis, Current Medicinal Chemistry (2020)
27. Evaluation of Microrna Expression Pattern (Mir-28, Mir-181A, Mir-34A, and Mir-31) in Patients With Covid-19 Admitted to Icu and Diabetic Covid-19 Patients, Intervirology (2023)
28. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
29. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
30. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
31. Evaluation of Silencing Effect of Mir-133A-5P Mimic on Tim-3 Expression in Aml (Hl-60) Cell Line, Indian Journal of Clinical Biochemistry (2020)
32. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
33. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
34. Micrornas As the Actors in the Atherosclerosis Scenario, Journal of Physiology and Biochemistry (2020)
35. Comparing Side Effects of Cinnovex With Avonex in Relapsing Remitting Multiple Sclerosis Patients, Journal of Isfahan Medical School (2009)
36. Semaphorin-3A As an Immune Modulator Is Suppressed by Microrna-145-5P, Cell Journal (2018)
37. First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis, Neurotherapeutics (2025)
38. Upregulation of Mtor, Rps6kb1, and Eif4ebp1 in the Whole Blood Samples of Iranian Patients With Multiple Sclerosis Compared to Healthy Controls, Metabolic Brain Disease (2020)
39. Unveiling Mesenchymal Stem Cells’ Regenerative Potential in Clinical Applications: Insights in Mirna and Lncrna Implications, Cells (2023)
40. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
41. Exploring Plasma Expression Levels of Mir-200C-3P, Mir-150, and Mir-155 in Sars-Cov-2 Positive and Negative Subjects, Future Virology (2024)
42. Microrna Profiles in Critically Ill Patients, Current Medicinal Chemistry (2024)
43. Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of Covid-19 in Multiple Sclerosis: A Menactrims Registry Based Study, Multiple Sclerosis and Related Disorders (2024)
44. A Functional Microrna Binding Site Variant in Il-23R Gene in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Is There Any Correlation?, Molecular Biology Reports (2022)
45. Efficacy and Safety of Rituximab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2023)
46. Can Mir-503 Be Used As a Marker in Diabetic Patients With Ischemic Stroke?, BMC Endocrine Disorders (2019)
47. Evaluation of the Effect of Tim-3 Suppression by Mir-498 and Its Effect on Apoptosis and Proliferation Rate of Hl-60 Cell Line, Pathology Research and Practice (2018)
48. The Role of Mir-16 and Mir-34A Family in the Regulation of Cancers: A Review, Heliyon (2025)
49. Effect of High Dose Vitamin D Intake on Interleukin-17 Levels in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Neuroimmunology (2015)
50. Mir-574, Mir-499, Mir-125B, Mir-106A, and Mir-9 Potentially Target Tgfbr-1 and Tgfbr-2 Genes Involving in Inflammatory Response Pathway: Potential Novel Biomarkers for Chronic Lymphocytic Leukemia, Pathology Research and Practice (2022)